Your AI-Trained Oncology Knowledge Connection!
Based on data from the phase 3 VISION trial, 177Lu-PSMA-617 may now be used to treat patients who were previously treated with androgen receptor pathway inhibitors plus taxane-based chemotherapy for metastatic prostate specific membrane antigen–positive castration-resistant prostate cancer.
The 6.5-year updated analysis of the phase 3 CheckMate 067 trial highlighted notable overall survival benefit with nivolumab alone or in combination with ipilimumab for patients with advanced melanoma.
Findings from a meta-analysis indicated that pathologic complete response is a notable predictor of outcomes in HER2-positive breast cancer.
Axel Merseburger, MD, PhD, spoke about implementing the treatment combination of enzalutamide plus docetaxel/prednisone for progressive castration-resistant prostate cancer from the PRESIDE trial into the real-world.
A survey of United States breast oncologists suggested that racial differences exist in the perceived barriers to accessing genetic counseling and testing for patients with breast cancer.
Sponsored by Atlantic Health System
Laurence Albigès, MD, PhD, speaks to the patient population included in the phase 3 CheckMate 214 trial, assessing nivolumab plus ipilimumab in patients with treatment-naïve advanced or metastatic renal cell carcinoma.
Survival among patients with multiple myeloma appears to be influenced by factors such as socioeconomic status and treatment facility type.
A survey suggests individuals with cancer who were undergoing active treatment were more likely to endorse COVID-19 related misinformation than those with no history of cancer.
Maurie Markman, MD, sits down with CancerNetwork® to discuss proposed legislation that would put a time limit on how long drugs with an accelerated approval can stay on the market, and how that may negatively impact patients with cancer.
Yelena Y. Janjigian, MD, spoke about which biomarkers were most predictive for treatment of localized gastric cancer.
Pembrolizumab has been approved by the FDA for the use in advanced microsatellite instability–high/mismatch repair–deficient endometrial cancer following prior systemic therapy.
Patients with mantle cell lymphoma appeared to benefit from brexucabtagene autoleucel as salvage therapy in the real-world setting.
7HP340 was granted fast track designation in combination with an anti–CTLA-4 treatment by the FDA for patients with unresectable or malignant melanoma for whom PD-1 inhibition therapy has failed.
For Kidney Cancer Awareness Month, CancerNetwork® spoke with Daniel M. Geynisman, MD, about how emerging data in the treatment of renal cell carcinoma stand to further impact the standard of care.
During the Association of Community Cancer Centers 48th Annual Meeting & Cancer Center Business Summit, Candice Roth, MSN, RN, CENP, spoke about electronic pathways embedded in electronic medical records.
A survival benefit was observed in patients with advanced or recurrent endometrial cancer who were treated with maintenance selinexor.
The phase 3 PRIME study showed increased progression-free survival for patients with newly diagnosed ovarian cancer who were treated with an individualized starting dose of maintenance niraparib vs placebo.
The iPocc trial indicated that patients with ovarian cancer experienced an improvement in progression-free survival when treated with intraperitoneal carboplatin plus paclitaxel compared with intravenous chemotherapy, but this benefit did not translate to overall survival.
Phase 3 SOROYA trial revealed promising response rates with mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer and high folate receptor–alpha expression.
Data presented at 2022 SGO from the phase 2 OVARIO trial show promise of niraparib plus bevacizumab in high-risk ovarian cancer treated with frontline platinum-based chemotherapy.
Patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy may experience promising responses and disease control following treatment with nemvaleukin alfa and pembrolizumab.
Results of the phase 1 NRG-GY017 trial show promise of atezolizumab as an immune primer in locally advanced cervical cancer.
Patients with BRCA-mutant, homologous repair deficiency–positive advanced resectable ovarian cancer may benefit from treatment with neoadjuvant niraparib, according to early results of a phase 2 trial reported at 2022 SGO.
Jhalak Dholakia, MD, discusses the promising neoadjuvant combination of of carboplatin and mirvetuximab soravtansine in folate receptor α–positive advanced-stage ovarian, fallopian tube, or primary peritoneal cancer.
Olaparib and non-platinum chemotherapy produced similar overall survival results when treating patients with platinum-sensitive, relapsed ovarian cancer with BRCA mutations.
No differences in overall and progression-free survival were observed at the GOG-0252 trial update among patients with ovarian cancer who were treated with intravenous or intraperitoneal chemotherapy plus bevacizumab.
Updated results from the KEYNOTE-826 study show a favorable risk-benefit ratio for pembrolizumab plus chemotherapy for patients with persistent, recurrent, or metastatic cervical cancer.
Olaparib maintenance therapy will be investigated after receiving first-line chemotherapy for patients with BRCA1/2 wild-type advanced ovarian cancer.
An anti-TIGIT/anti–PD-1 combination approach with ociperlimab plus tislelizumab will be examined in a phase 2 study of patients with previously treated recurrent or metastatic cervical cancer.
